Dr. Lisa Kroon is a Professor of Clinical Pharmacy in the Department of Clinical Pharmacy in the School of Pharmacy at the University of California in San Francisco. She holds an executive pharmacy leadership role at UCSF Health since 2020, where she was appointed the Assistant Chief Pharmacy Officer for Clinical Innovation, Education, and Research for the Pharmacy Enterprise, where she oversees ambulatory pharmacy practice. Dr.
Dr. Levine has researched pain and analgesia for more than 40 years. His areas of research include mechanisms of pain in inflammatory diseases, neuropathic pain, and stress in chronic widespread pain syndromes; mechanisms that mediate the transition from acute to chronic pain; biology of pain differences between men and women; and the mechanism of the placebo effect.
Dr. Daniel H. Lowenstein is the Executive Vice Chancellor and Provost, and the Robert B. and Ellinor Aird Professor of Neurology in the Department of Neurology at the University of California, San Francisco ( UCSF).
American Cancer Society Clinical Research Professor
Sharon Lamb Endowed Chair in Symptom Management Research
Physiological Nursing
Dr. Miaskowski's research focuses on identifying patients who are at greatest risk for more severe cancer pain syndromes and the molecular mechanisms that underlie these pain problems. Her laboratory has made seminal contributions to our understanding of chronic pain after breast cancer surgery and chemotherapy-induced peripheral neuropathy.
Dr. Schumacher's research focuses on the identification of novel analgesic targets in the peripheral nervous system to treat chronic pain without risk of addiction. Currently, he is investigating a class of transcription inhibitors previously used to treat cancer that now show promise to block pain from inflammation and nerve injury.
Matthew W. State MD, PhD, is a child psychiatrist and human geneticist studying pediatric neuropsychiatric syndromes. His lab focuses on gene discovery as a launching point for efforts to illuminate the biology of these conditions and to develop novel and more effective therapies.
